Wells Fargo & Company Cuts Septerna (NASDAQ:SEPN) Price Target to $11.00

Septerna (NASDAQ:SEPN) had its price target trimmed by Wells Fargo & Company from $14.00 to $11.00 in a research note published on Friday,Benzinga reports. The brokerage currently has an equal weight rating on the stock.

Separately, Cantor Fitzgerald restated an “overweight” rating and set a $50.00 price objective on shares of Septerna in a research note on Tuesday, February 11th.

Septerna Trading Down 3.0 %

NASDAQ SEPN opened at $6.10 on Friday. Septerna has a 52 week low of $4.17 and a 52 week high of $28.99. The company has a 50 day moving average price of $9.96.

Septerna (NASDAQ:SEPN) last announced its quarterly earnings data on Thursday, March 27th. The company reported ($0.64) EPS for the quarter, topping analysts’ consensus estimates of ($0.69) by $0.05. The business had revenue of $0.21 million during the quarter, compared to the consensus estimate of $0.13 million. As a group, equities analysts expect that Septerna will post -7.11 EPS for the current year.

Insider Activity

In other news, Director Alan Ezekowitz bought 41,355 shares of the business’s stock in a transaction that occurred on Thursday, March 6th. The stock was acquired at an average cost of $6.00 per share, for a total transaction of $248,130.00. Following the purchase, the director now owns 104,101 shares of the company’s stock, valued at approximately $624,606. This trade represents a 65.91 % increase in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Also, CFO Gil M. Labrucherie purchased 10,500 shares of the stock in a transaction on Wednesday, February 19th. The shares were acquired at an average cost of $5.51 per share, for a total transaction of $57,855.00. Following the transaction, the chief financial officer now owns 10,500 shares of the company’s stock, valued at approximately $57,855. The trade was a ∞ increase in their ownership of the stock. The disclosure for this purchase can be found here. In the last 90 days, insiders purchased 74,346 shares of company stock valued at $439,670.

Institutional Investors Weigh In On Septerna

A number of large investors have recently added to or reduced their stakes in the business. Tower Research Capital LLC TRC bought a new position in Septerna during the fourth quarter worth $25,000. New York State Common Retirement Fund bought a new stake in shares of Septerna during the 4th quarter worth about $32,000. Legal & General Group Plc bought a new stake in shares of Septerna during the 4th quarter worth about $42,000. Summit Investment Advisors Inc. acquired a new position in Septerna in the 4th quarter valued at about $45,000. Finally, BNP Paribas Financial Markets bought a new position in Septerna in the 4th quarter valued at about $52,000.

About Septerna

We are a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by our proprietary Native Complex Platform™. Our industrial-scale platform aims to unlock the full potential of GPCR therapies and has led to the discovery and development of our deep pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases.